Research

A Phase 2a, Prospective, Randomized, DoubleBlind, Placebo Controlled, Single and Repeat-Dose, Multicenter, Exploratory Efficacy Study of FX-322 Administered by Intratympanic Injection in Adults with Stable Sensorineural Hearing Loss

Eligibility: Participants must be between 18-65 years old with an established diagnosis of stable sensorineural hearing loss by standard hearing tests.
Goal: To evaluate a new investigational medication called FX-322 that is delivered directly in the ear through the eardrum.
Contact Info: Auditory Rehabilitation & Clinical Trials (ARCT) Lab; Email: arctlab@usf.edu; Phone: 813.974.1262; Mention the "Fx322" Study

Lead Otologist, Principal Investigator: K. Paul Boyev, MD 
Lead Audiologist, Investigator: Victoria Sanchez, AuD, PhD 
Advarra IRB Pro00037316

Are you or someone you know struggling with hearing loss? What if a simple, locally-delivered drug could enable our ear to regenerate and heal itself?

Researchers from the Auditory Rehabilitation and Clinical Trials Laboratory (ARCT Lab) within the Department of Otolaryngology are conducting a clinical trial to evaluate a new investigational medication called FX-322 that is delivered directly in the ear through the eardrum.

The study will take place over a minimum of 12 visits across 8 months and includes four ear injections.

The study is being funded by Frequency Therapeutics, Inc., a company dedicated to eradicating hearing loss. There will be no cost to the participant or the participant’s insurance company. Participants will be compensated for their time.